Cart
sales@molnova.com
Home - Products - Angiogenesis - EGFR - Alflutinib

Alflutinib

CAS No. 1869057-83-9

Alflutinib ( AST2818;AST-2818;ASK120067 )

Catalog No. M12888 CAS No. 1869057-83-9

Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 412 Get Quote
10MG 588 Get Quote
25MG 888 Get Quote
50MG 1251 Get Quote
100MG 1692 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Alflutinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
  • Description
    Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical
  • Synonyms
    AST2818;AST-2818;ASK120067
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    1869057-83-9
  • Formula Weight
    568.61
  • Molecular Formula
    C28H31F3N8O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C
  • Chemical Name
    N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • CK-101

    CK-101 (RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC.

  • Lapatinib ditosylate

    A reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • Matuzumab

    Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.

Sign In Join Free